Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer

Authors: Xu Shi, Dechao Feng, Dengxiong Li, Ping Han, Lu Yang, Wuran Wei

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Apolipoprotein F (APOF) has been less studied in cancers. Thus, we aimed to perform a pan-cancer analysis of the oncogenic and immunological effects of APOF on human cancer.

Methods

A standardized TCGA pan-cancer dataset was downloaded. Differential expression, clinical prognosis, genetic mutations, immune infiltration, epigenetic modifications, tumor stemness and heterogeneity were analyzed. We conducted all analyses through software R (version 3.6.3) and its suitable packages.

Results

Overall, we found that the common cancers differentially expressed between tumor and normal samples and prognostic-associated were BRCA, PRAD, KIRP, and LIHC in terms of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). The pan-cancer Spearman analysis showed that the mRNA expression of APOF was negatively correlated with four tumor stemness indexes (DMPss, DNAss, ENHss, and EREG-METHss) with statistical significance for PRAD and was positively correlated for LIHC. In terms of BRCA and PRAD patients, we found negative correlation of APOF with TMB, MSI, neo, HRD and LOH. The mutation frequencies of BRCA and LIHC were 0.3%. APOF expression was negatively correlated with immune infiltration and positively correlated with tumor purity for PRAD patients. The mRNA expression of APOF was negatively associated with most TILs for LIHC, B cells, CD4+ T cells, neutrophils, macrophages and dendritic cells, but was positively associated with CD8+ T cells.

Conclusions

Our pan-cancer study offered a relatively comprehensive understanding of the roles of APOF on BRCA, PRAD, KIRP, and LIHC.
Appendix
Available only for authorised users
Literature
1.
Olofsson SO, McConathy WJ, Alaupovic P. Isolation and partial characterization of a new acidic apolipoprotein (apolipoprotein F) from high density lipoproteins of human plasma. Biochemistry. 1978;17(6):1032–6.PubMedCrossRef
2.
Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406.PubMedCrossRef
3.
Deprince A, Hennuyer N, Kooijman S, Pronk ACM, Bauge E, Lienard V, et al. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism. Hepatology. 2023;77(4):1287–302.PubMedCrossRef
4.
Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem. 1999;274(3):1814–20.PubMedCrossRef
5.
Liu Y, Morton RE. Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism. Curr Opin Lipidol. 2020;31(4):194–9.PubMedPubMedCentralCrossRef
6.
Morton RE, Liu Y, Izem L. ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters. J Lipid Res. 2019;60(11):1868–79.PubMedPubMedCentralCrossRef
7.
Lagor WR, Brown RJ, Toh SA, Millar JS, Fuki IV, de la Llera-Moya M, et al. Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler Thromb Vasc Biol. 2009;29(1):40–6.PubMedCrossRef
8.
Morton RE, Gnizak HM, Greene DJ, Cho KH, Paromov VM. Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects. J Lipid Res. 2008;49(1):127–35.PubMedCrossRef
9.
Croyal M, Wargny M, Chemello K, Chevalier C, Blanchard V, Bigot-Corbel E, et al. Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovasc Diabetol. 2022;21(1):21.PubMedPubMedCentralCrossRef
10.
11.
Du Y, Liu Y, Cao J, Jiang X, Wang Y, Yu J, et al. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer. Front Immunol. 2023;14:1113756.PubMedPubMedCentralCrossRef
12.
Chang LC, Hsu YC, Chiu HM, Ueda K, Wu MS, Kao CH, et al. Exploration of the proteomic landscape of small extracellular vesicles in serum as biomarkers for early detection of colorectal neoplasia. Front Oncol. 2021;11: 732743.PubMedPubMedCentralCrossRef
13.
Da Z, Gao L, Su G, Yao J, Fu W, Zhang J, et al. Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma. Cancer Cell Int. 2020;20:130.PubMedPubMedCentralCrossRef
14.
Wang YB, Zhou BX, Ling YB, Xiong ZY, Li RX, Zhong YS, et al. Decreased expression of ApoF associates with poor prognosis in human hepatocellular carcinoma. Gastroenterol Rep (Oxf). 2019;7(5):354–60.PubMedCrossRef
15.
Dickinson A, Saraswat M, Syrjanen S, Tohmola T, Silen R, Randen-Brady R, et al. Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients. PLoS ONE. 2020;15(6): e0233974.PubMedPubMedCentralCrossRef
16.
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–27.PubMedCrossRef
17.
Zhu W, Feng D, Shi X, Li D, Wei Q, Yang L. A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer. Front Oncol. 2022;12:1042118.
18.
Feng D, Shi X, Zhu W, Zhang F, Li D, Han P, et al. A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. Exp Hematol Oncol. 2022 Sep 15;11(1):55.
19.
Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8.PubMedPubMedCentralCrossRef
20.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–16.PubMedPubMedCentralCrossRef
21.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–54.PubMedPubMedCentralCrossRef
22.
23.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.PubMedPubMedCentralCrossRef
24.
25.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.PubMedPubMedCentralCrossRef
26.
Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef
27.
Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12: 687975.PubMedPubMedCentralCrossRef
28.
Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–2.PubMedCrossRef
29.
Morton RE, Greene DJ. Regulation of lipid transfer between lipoproteins by an endogenous plasma protein: selective inhibition among lipoprotein classes. J Lipid Res. 1994;35(5):836–47.PubMedCrossRef
30.
He Y, Greene DJ, Kinter M, Morton RE. Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex. J Lipid Res. 2008;49(7):1529–37.PubMedPubMedCentralCrossRef
31.
32.
Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res. 2010;51(12):3524–32.PubMedPubMedCentralCrossRef
33.
Conlon DM, Thomas T, Fedotova T, Hernandez-Ono A, Di Paolo G, Chan RB, et al. Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. J Clin Invest. 2016;126(10):3852–67.PubMedPubMedCentralCrossRef
34.
Parcon PA, Balasubramaniam M, Ayyadevara S, Jones RA, Liu L, Shmookler Reis RJ, et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers Dement. 2018;14(2):230–42.PubMedCrossRef
35.
Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004;64(5):1834–42.PubMedCrossRef
36.
Bajo-Graneras R, Crespo-Sanjuan J, Garcia-Centeno RM, Garrote-Adrados JA, Gutierrez G, Garcia-Tejeiro M, et al. Expression and potential role of apolipoprotein D on the death-survival balance of human colorectal cancer cells under oxidative stress conditions. Int J Colorectal Dis. 2013;28(6):751–66.PubMedCrossRef
37.
Zhaorigetu S, Yang Z, Toma I, McCaffrey TA, Hu CA. Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells. J Biol Chem. 2011;286(31):27389–98.PubMedPubMedCentralCrossRef
38.
Yiu CC, Sasano H, Ono K, Chow LW. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Expert Opin Investig Drugs. 2010;19(Suppl 1):S79-89.PubMedCrossRef
39.
Cruz IN, Coley HM, Kramer HB, Madhuri TK, Safuwan NA, Angelino AR, et al. Proteomics analysis of ovarian cancer cell lines and tissues reveals drug resistance-associated proteins. Cancer Genomics Proteomics. 2017;14(1):35–51.PubMedCrossRef
40.
Guillemot J, Essalmani R, Hamelin J, Seidah NG. Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio. 2014;4:741–5.PubMedPubMedCentralCrossRef
41.
Lagor WR, Fields DW, Khetarpal SA, Kumaravel A, Lin W, Weintraub N, et al. The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice. PLoS ONE. 2012;7(2): e31616.PubMedPubMedCentralCrossRef
42.
Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189–94.PubMedPubMedCentralCrossRef
43.
Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45(9):1594–607.PubMedCrossRef
44.
Morton RE, Greene DJ. Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition. J Lipid Res. 2011;52(12):2262–71.PubMedPubMedCentralCrossRef
45.
Gupta A, Stokes W, Eguchi M, Hararah M, Amini A, Mueller A, et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol. 2019;90:54–66.PubMedPubMedCentralCrossRef
46.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.PubMedPubMedCentralCrossRef
47.
Yang Y, Fu Q, Zhou T, Li Y, Liu S, Zeng Q, et al. Analysis of apolipoprotein genes and their involvement in disease response of channel catfish after bacterial infection. Dev Comp Immunol. 2017;67:464–70.PubMedCrossRef
48.
Dechao Feng DL, Ruicheng Wu , Ping Han. Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCO-GU Cancers Symposium. Aging and disease. 2023.
49.
Shen W, He J, Hou T, Si J, Chen S. Common Pathogenetic Mechanisms Underlying Aging and Tumor and Means of Interventions. Aging Dis. 2022 Jul 11;13(4):1063–91.
50.
Schwartz AG. Dehydroepiandrosterone, Cancer, and Aging. Aging Dis. 2022 Apr;13(2):423–32.
51.
Xu Z, Huang J, Gao M, Guo G, Zeng S, Chen X, et al. Current perspectives on the clinical implications of oxidative RNA damage in aging research: challenges and opportunities. Geroscience. 2021 Apr;43(2):487–505.
52.
Zhu WZ, Feng DC, Xiong Q, Shi X, Zhang FC, Wei Q, et al. An autophagy-related gene prognostic index predicting biochemical recurrence, metastasis, and drug resistance for prostate cancer. Asian J Androl. 2023 Mar-Apr;25(2):208–16.
53.
Weitao Zheng DF, Xingyu Xiong, Xinyang Liao, Sheng Wang, Hang Xu, Weizhen Le, Qiang Wei, Lu Yang. The Role of cGASSTING in Age-Related Diseases from Mechanisms to Therapies. Aging and Disease. 2023.
54.
Feng DC, Zhu WZ, Shi X, Xiong Q, You J, Wei Q, et al. Identification of senescence-related molecular subtypes and key genes for prostate cancer. Asian J Androl. 2023 Mar-Apr;25(2):223–9.
55.
Feng D, Zhu W, Shi X, Wang Z, Wei W, Wei Q, et al. Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy. Exp Hematol Oncol. 2023 Jan 12;12(1):8.
56.
Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023 Feb;168(2):199–202.
57.
Feng D, Zhu W, Shi X, Xiong Q, Li D, Wei W, et al. Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer. Exp Hematol Oncol. 2022 Oct 20;11(1):76.
58.
Feng D, Zhang F, Li D, Shi X, Xiong Q, Wei Q, et al. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer. Immunology. 2022 Jun;166(2):197–209.
59.
Feng D, Xiong Q, Zhang F, Shi X, Xu H, Wei W, et al. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer. Front Immunol. 2022;13:777724.
60.
Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2022 Feb 10.
61.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy. Front Immunol. 2022;13:839362.
62.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Mitochondria Dysfunction-Mediated Molecular Subtypes and Gene Prognostic Index for Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy. Front Oncol. 2022;12:858479.
63.
Feng D, Shi X, You J, Xiong Q, Zhu W, Wei Q, et al. A cellular senescence-related gene prognostic index for biochemical recurrence and drug resistance in patients with prostate cancer. Am J Cancer Res. 2022;12(8):3811–28.
64.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, et al. A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy. Front Cell Dev Biol. 2022;10:803766.
65.
Feng D, Li D, Shi X, Xiong Q, Zhang F, Wei Q, et al. A gene prognostic index from cellular senescence predicting metastasis and radio resistance for prostate cancer. J Transl Med. 2022 Jun 3;20(1):252.
66.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Yang L. A Gene Prognostic Index Associated With Epithelial-Mesenchymal Transition Predicting Biochemical Recurrence and Tumor Chemoresistance for Prostate Cancer. Front Oncol. 2021;11:805571.
67.
Feng D, Wang J, Shi X, Li D, Wei W, Han P. Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients. Eur J Med Res. 2023 May 13;28(1):172.
68.
Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–8.PubMedPubMedCentralCrossRef
69.
Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014;14:132.PubMedPubMedCentralCrossRef
70.
71.
Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 2013;32(8):961–7.PubMedCrossRef
72.
Lincoln DW 2nd, Phillips PG, Bove K. Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model. Breast Cancer Res Treat. 2003;78(2):167–78.PubMedCrossRef
73.
Shen XB, Huang L, Zhang SH, Wang DP, Wu YL, Chen WN, et al. Transcriptional regulation of the apolipoprotein F (ApoF) gene by ETS and C/EBPalpha in hepatoma cells. Biochimie. 2015;112:1–9.PubMedCrossRef
74.
75.
76.
Allott EH, Freedland SJ. Words of wisdom. Re: impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. Eur Urol. 2013;63(1):178–9.PubMedCrossRef
77.
Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9(4):358–65.PubMedCrossRef
78.
Heemers HV, Verhoeven G, Swinnen JV. Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol. 2006;20(10):2265–77.PubMedCrossRef
79.
Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, et al. Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Lab Invest. 2008;88(10):1049–56.PubMedCrossRef
80.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
81.
Gonias SL, Karimi-Mostowfi N, Murray SS, Mantuano E, Gilder AS. Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival. PLoS ONE. 2017;12(10): e0186649.PubMedPubMedCentralCrossRef
82.
Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2015;112(8):2473–8.PubMedPubMedCentralCrossRef
83.
Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 2013;73(15):4722–31.PubMedCrossRef
84.
Ma XL, Gao XH, Gong ZJ, Wu J, Tian L, Zhang CY, et al. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget. 2016;7(43):70654–68.PubMedPubMedCentralCrossRef
85.
Izem L, Morton RE. Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia. J Lipid Res. 2009;50(4):676–84.PubMedPubMedCentralCrossRef
86.
87.
Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65(3):579–88.PubMedPubMedCentralCrossRef
88.
Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429–43.PubMedCrossRef
89.
Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596–607.PubMedCrossRef
90.
Morton RE, Nunes V, Izem L, Quintao E. Markedly elevated lipid transfer inhibitor protein in hypercholesterolemic subjects is mitigated by plasma triglyceride levels. Arterioscler Thromb Vasc Biol. 2001;21(10):1642–9.PubMedCrossRef
91.
Tugnoli V, Trinchero A, Tosi MR. Evaluation of the lipid composition of human healthy and neoplastic renal tissues. Ital J Biochem. 2004;53(4):169–82.PubMed
92.
Li L, Liu H, Peng J, Wang Y, Zhang Y, Dong J, et al. Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice. Biochem Biophys Res Commun. 2013;441(4):880–5.PubMedCrossRef
93.
Liu Y, Izem L, Morton RE. Identification of a hormone response element that mediates suppression of APOF by LXR and PPARalpha agonists. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(3): 158583.PubMedCrossRef
Metadata
Title
A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer
Authors
Xu Shi
Dechao Feng
Dengxiong Li
Ping Han
Lu Yang
Wuran Wei
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01156-w

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

RNA-seq research landscape in Africa: systematic review reveals disparities and opportunities

Research

CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling

Research

Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis

Research

A dynamic online nomogram for predicting death in hospital after aneurysmal subarachnoid hemorrhage

Review

Tumor immune microenvironment (TIME) to enhance antitumor immunity

Research

Bidirectional association between infectious gastroenteritis and inflammatory bowel disease: a population-based study